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ABSTRACT
Objective: The objective of the current study is to compare the levels of oxidative stress markers malondialdehyde (MDA), zinc, and antioxidant 
Vitamins (A, E, and C) in ischemic heart disease (IHD) and non-IHD patients with diabetes mellitus.
Method: This is cross-sectional study group, conducted in the advanced diagnostic center (Khartoum- Sudan) from the period May 2013 to August 
2015. Comprised 100 healthy subjects were, control group with mean (fasting blood sugar) 5.61=m mol/L, the age ranged from 22 to 78 years old, 
the average of the age was 50.1 years. 300 patients (78 IHD and 222 without) as cases groups, the ages ranged from 30 to 80 years. The age average 
was 51.2 years, all samples were in a state of fasting for 12 h, and the data were collected using a structured questionnaire and direct interview to 
collect information. Blood specimens were collected from both groups, and plasma levels of MDA, zinc, and antioxidant Vitamins (A, E, and C) were 
determined.
Results: There was a significant difference between the level of serum Vitamin A, E, Zinc and MDA in diabetic patients with IHD and those diabetic 
without IHD (p<0.05). No significant differences in serum Vitamin C level between both groups (p>0.05).
Conclusion: Due to the significant differences in serum Vitamin A, E, Zinc, and MDA between diabetics with IHD and diabetics without IHD, these 
parameters can be used as prognostic markers for prediction of oxidative stress and antioxidant stress of diabetic patients with IHD complications.
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INTRODUCTION
Diabetes mellitus (DM) is a chronic metabolic disorder manifested 
in the form of hyperglycemia as a consequence of a defect in insulin 
secretion and/or insulin action along with an imbalance in the 
metabolism of carbohydrates, fats, and proteins [1]. Hyperglycemia 
or raised blood sugar is a common effect of uncontrolled diabetes 
and over time leads to serious damage to many of the body’s systems, 
especially the nerves and blood vessels [2]. Type two DM diabetes 
is a major risk factor for developing macrovascular complications, 
including atherosclerosis, myocardial infarction, stroke, and 
peripheral vascular disease. In adults with diabetes, the risk of death 
from heart disease and stroke is 2–4 times higher than in adults 
without diabetes’s [3]. Oxidative stress is closely associated with the 
pathogenesis of diabetes mellitus and results from overproduction 
of reactive oxygen species and overproduction is associated with 
hyperglycemia and metabolic disorders, such as impaired antioxidant 
function in conjunction with impaired antioxidant activity [4]. 
Apart from the traditional risk factors such as arterial hypertension, 
dyslipidemia, and obesity, hyperglycemia is an independent risk factor 
for the development of ischemic heart disease (IHD). The course of IHD 
in diabetic patients is usually more complicated [5]. Oxidative stress 
alters normal endothelial function, supporting pro-inflammatory, 
prothrombotic, proliferative, and vasoconstrictor mechanism that 
favors the development of atherosclerosis and vascular tissue injury. 
The pathogenesis of atherosclerosis involves damage to the capillary 
endothelium caused by various factors including oxidized low-
density lipoprotein [6]. The aim of the current study was to evaluate 
and compare the levels of oxidative stress markers malondialdehyde 
(MDA), zinc, and antioxidant Vitamins (A, E, and C) in IHD and non-IHD 
patients with DM.
METHOD
This study was conducted in Khartoum state in the advanced diagnostic 
center from the period May 2013 to August 2015. 100 healthy subjects 
were control group with mean fasting blood sugar (FBS) 5.61=m mol/L. 
The age ranged from 22 to 78 years old. The age average was 50.1 years. 
Type 2 diabetic patients were 300 (78 IHD and 222 without), the ages 
ranged from 30 to 80 years old. The age average was 51.2 years. All 
samples were collected after 12 h fasting. MDA in serum performed by 
mixing with 20% trichloroacetic acid and incubated for 10 min. After 
that 0.05 ml of H2So4 and thiobarbituric acid were added. The mixture 
was mixed and place in 70°C water bath for 30 min. The resulting 
chromogen was extracted with n-butanol and centrifuged at 2000 rpm/
min, and measured against butanol blank at 532 nm excitation and 
553 nm emission by spectrophotometer. The antioxidant Vitamins (A, C, 
E, and Zinc) were assayed by high-performance liquid chromatography. 
In the samples, the peak height (area) ratio was determined, and the 
appropriate plasma retinol (Vitamin A) and the appropriate plasma 
tocopherol (Vitamin E) concentrations were determined from the 
standard curve (regression line formula, Vitamin A and E were detected 
at 290 nm. The Vitamin C was identified by comparing the retention 
time of the sample peak with that of the Vitamin C standard at 245 nm. 
Zinc present in the sample is chelated by 5-Br-PAPS 2-(5-bromo-2-
pyridylazo)-5-(N-propyl-N-sulfopropylamino)-phenol in the reagent. 
The formation of this complex is measured at a wavelength of 
560 nm [7]. The study was approved by in advanced diagnostic center, 
in Khartoum. All samples were taken from the participants after they 
agreed and fill the questionnaire. Statistical Package for the Social 
Sciences (version 13) computer software was used for data analysis. 
The means and standard deviations of a variable calculated and t-test 
were used for comparison (significant level was set at p≤0.05).
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RESULTS
The general characteristics of the subjects (case and control) included in the 
study are listed in Table 1. There is no significant difference in age between 
the two groups age mean±standard deviation (SD) was 50.1±14.0 for the 
control group versus 51.2±11.1 for the test group (p=0.06). Weight and 
height showed significant differences between the test and control group. 
Weight Mean±SD was 74.5±12.2 kg for the control group and 79.7±22.8 kg 
for the test group (p=0.032). Height Mean±SD was 171±10.0 cm for the 
control group and was 164±10.0 for the test group (p=0.0006). Shows a 
highly significant difference between the mean of test group (n=300) and 
the mean of control group (n=100) in FBS Mean±SD: (160±65.5) versus 
(101±11.9) mg/dl, respectively (p = 0.002), Serum vitamin A ,Mean±SD: 
(50.3±20.0) versus (81.2±21.8) µg/dl, respectively (p = 0.001), serum 
vitamin E Mean±SD: (5.2±1.8) versus (15.6±4.8) µg/ml, respectively 
(p = 0.001),serum vitamin C , Mean±SD: (3.9±1.3) versus (10±2.2) µg/ml, 
respectively (p = 0.0003) and plasma MDA ,Mean±SD: (6.7±6.2) versus 
(2.4±1.1) n mol/l, respectively (p = 0.001) and Serum zinc Mean±SD: 
(77.2±9.8) versus (100.5±12.9) µg/l, respectively (P = 0.001).
78 of the test group (26%) have IHD, whereas 222 of them 74% have 
no heart disease. A significant difference between the means of serum 
Vitamin A of the test group with IHD (n=78) and those without IHD 
(n=222). Mean±SD: 45.8±21.6 versus 51.9±19.2 µg/dl, respectively 
(p=0.022). A significant difference between the means of serum Vitamin 
E in the test group with IHD (n=78) and those without IHD (n=222). 
Mean±SD: 4.8±1.8 versus 5.3±1.8 µg/ml, respectively (p=0.023). 
Insignificant difference between the means of serum Vitamin C in the 
test group with IHD (n=78) and those without IHD (n=222). Mean±SD: 
3.8±1.3 versus 4.0±1.3 µg/ml, respectively (p=0.234). A significant 
difference between the means of plasma MDA of the test group with 
IHD (n=78) and those without IHD (n=222). Mean±SD: 12.2±8.5 versus 
4.8±3.6 n mol/l, respectively (p=0.04). A significant difference between 
the means of serum zinc of the test group with IHD (n=78) and those 
without IHD (n=222). Mean±SD: 75.4±10.3 versus 77.9±9.5 µg/l, 
respectively (p=0.05) (Table 2).
DISCUSSION
In the present study, we have determined the main oxidative stress 
markers among diabetic patients with IHD complication and non-IHD. 
Our results showed that serum MDA is a highly significant difference 
between the means of serum MDA of patients with IHD and the 
patient’s group without heart disease. This concept is analogous to that 
described by Shabana and Steve, observed significantly different blood 
levels of MDA among patients with chronic heart disease which were 
indicating overall oxidative stress in those patients [8]. This result also 
is consistent with another study conducted by Khan, and Abdul Baseer 
reported that the elevated serum levels of MDA indicate an increase in 
the level of production of oxygen free radicals, suggesting their possible 
role in atherogenesis, leading to coronary heart disease [9,10]. The 
results of the study also indicated a highly significant increase in the 
levels of serum antioxidant Vitamins A and E of patients with IHD and 
the patient’s group without heart disease. Our findings are in agreement 
with those of other authors who showed serum Vitamin A and Vitamin 
E levels in patients with chronic heart disease were found to be lower 
than without heart disease [11-13]. On the other hand, some reports 
indicate that no significant changes occur in patients with heart disease 
when compare to patients without heart disease [14,15]. Reduced 
levels of Vitamin E may also be due to the increased requirement of 
Vitamin E in pro-oxidant milieu with enhanced free radical status, 
leading to the increased lipid peroxidation, a resultant depletion of 
free radical scavenger, and antioxidant reserves of the body [16]. The 
findings showed that there is no significant change between the means 
of serum Vitamin C in the test group with IHD and those without IHD. 
Our finding supported by some cohort studies and randomized trials 
have shown no relationship between Vitamin C intake and heart disease 
risk [17,18]. The results disagreed with many studies reported that 
Table 1: Baseline characteristics of the respondents and comparison of the means of blood parameters between diabetics and none 
diabetics 
Variables Control (none‑diabetics) (n=100) Test group (diabetics) (n=300) p
Age (years) 50.1±14.0 51.2±11.1 0.06**
(Max-Min) (22.0–78.0) (23.0–80.0)
Weight (kg) 74.5±12.2 79.7±22.8 0.032*
(Max-Min) (52.0–105.0) (50.0–180.0)
Height (m) 171±10.0 164±10.0 0.0006*
(Max-Min) (152–196) (135–190)
FBS 101.5±11.9 160.4±65.5 0.0002*
(Max-Min) (70.0–120.0) (75.0–480.0)
Vitamin A 81.2±21.8 50.3±20.0 0.001*
(Max-Min) (10.0–133.0) (14.0–95.0)
Vitamin E 15.6±4.8 5.2±1.8 0.001*
(Max-Min) (3.5–24.0) (1.0–9.0)
Vitamin C 10.0±2.2 3.9±1.3 0.0003*
(Max-Min) (4.6–18.0) (1.2–6.9)




(100.5±12.9) µg/l (77.2±9.8) 0.001
*Significant differences in weight, height, serum Vitamin A, C, E, FBS, Zinc, and MDA between control and test group (p<0.05). **No significant differences in age.  
MDA: Malondialdehyde, FBS: Fasting blood sugar
Table 2: Comparison of blood parameters among test group 
according to IHD
Variables IHD N (78) Non‑IHD N (222) p
FBS 159.0±54.2 160.9±69.2 0.822**
(Max-Min) (86.0–326.0) (75.0–480.0)
Vitamin A 45.8±21.6 51.9±19.2 0.022*
(Max-Min) (15.0–92.0) (14.0–95.0)
Vitamin E 4.8±1.8 5.3±1.8 0.023*
(Max-Min) (1.9–8.9) (1.0–9.0)
Vitamin C 3.8±1.3 4.0±1.3 0.234**
(Max-Min) (1.2–6.9) (1.2–6.8)
MDA 12.2±8.5 4.8±3.6 0.04*
(Max-Min) (1.2–35.0) (1.0–20.0)
Zinc 75.4±10.3 77.9±9.5 0.05*
(Max-Min) (55.0–95.0) (55.0–95.0)
*Significant differences in Serum Vitamin A and E, Zinc, MDA between 
diabetics with ischemic heart disease and diabetics without ischemic heart 
disease (p<0.05). **No significant differences in Serum Vitamin C and 
FBS (p>0.05). MDA: Malondialdehyde, FBS: Fasting blood sugar, IHD: Ischemic 
heart disease
510
Asian J Pharm Clin Res, Vol 11, Issue 8, 2018, 508-510
 Eltom et al. 
there was significant association between Vitamin C and chronic heart 
disease [19,20]. Our results showed that serum zinc is a significant 
difference between the means of serum zinc of patients with IHD and 
the patient’s group without heart disease. Our finding is supported by 
many results indicate that there is a significant association between 
low serum zinc levels and heart disease [21,22]. On the other hand, in 
large cohort conducted among type 2 diabetic patients, concluded that 
low serum zinc level was an independent risk factor for heart disease 
events [23]. Furthermore, Soinio et al. concluded that low serum levels 
of zinc can be an independent risk factor of coronary artery disease. 
Low serum Zn levels in the IHD patient group may be related to 
excess release of steroids due to the release of leukocyte endogenous 
mediators which redistribute the body Zn from serum and may cause 
a drop in serum Zn and also due to elevated levels of α2-macroglobulin 
which is a transport protein containing large amounts of Zn [24,25]. 
The limitations of the study included relatively small sample size 
(seventy-eight) diabetic patients with IHD and inability to include more 
biochemical and anthropometric measures such as, glutathione, and 
glycerophospholipids to observe the real oxidative stress change as 
a complication of heart disease. The findings of this study should be 
replicated in larger cohorts in the future with more oxidative stress 
parameter and also include sex, ethnic, smoking, dietary habits, and 
family history.
CONCLUSION
This study shows that antioxidant status is impaired in diabetics 
patients with IHD compared to diabetic patients without IHD. 
Significant differences in serum Vitamin A, E, Zinc, and MDA between 
diabetics with IHD and diabetics without IHD can be used (A, E, Zinc, 
and MDA) as prognostic markers for prediction of oxidative stress and 
antioxidant stress of diabetic patients with IHD complications.
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